1-4 of 4
A. Bruce Lyons
Close
Sort by
Journal Articles

Dasatinib suppresses in vitro natural killer cell cytotoxicity

Stephen J. Blake, A. Bruce Lyons, Cara K. Fraser, John D. Hayball, Timothy P. Hughes
Journal: Blood
Blood (2008) 111 (8): 4415–4416.
https://doi.org/10.1182/blood-2008-02-138701
Published: 2008
Journal Articles

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML

Clinical Trials & Observations
Deborah White, Verity Saunders, A. Bruce Lyons, Susan Branford, Andrew Grigg, L. Bik To, Timothy Hughes
Journal: Blood
Blood (2005) 106 (7): 2520–2526.
https://doi.org/10.1182/blood-2005-03-1103
Published: 2005
Journal Articles

Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib

Andrea L. Dewar, Antony C. Cambareri, Andrew C. W. Zannettino, Bernadette L. Miller, Kathleen V. Doherty, Timothy P. Hughes, A. Bruce Lyons
Journal: Blood
Blood (2005) 105 (8): 3127–3132.
https://doi.org/10.1182/blood-2004-10-3967
Published: 2005
Journal Articles

Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) acts as a regulator of B-cell development, B-cell antigen receptor (BCR)–mediated activation, and autoimmune disease

Ray Wilkinson, A. Bruce Lyons, Donna Roberts, Mae-Xhum Wong, Paul A. Bartley, Denise E. Jackson
Journal: Blood
Blood (2002) 100 (1): 184–193.
https://doi.org/10.1182/blood-2002-01-0027
Published: 2002